Impact of the removal of the monthly liver function test requirement for ambrisentan.

导出 LinkOut

翻译打印收藏纠错

作者： Louise A,Durst ^[1] ; John,Carlsen ^[2] ; Megan,Kuchinski ^[3] ; Lauren,Harner ^[4] ; Daniel,Neves ^[4] ; Stephanie J,Harris ^[5] ; Glenna L,Traiger ^[6]

作者单位： Registered Nurse Research Study Coordinator, Mayo Clinic, Rochester, MN. ^[1] Vice President, Covance Market Access Services Inc, Gaithersburg, MD. ^[2] Director, Covance Market Access Services Inc, Gaithersburg, MD. ^[3] Associate, Covance Market Access Services Inc, Gaithersburg, MD. ^[4] Nurse Coordinator, Pulmonary Vascular Disease Program, University of Washington Medical Center, Seattle. ^[5] Pulmonary Hypertension CNS, Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA. ^[6]

PMID 24991314

发布时间 2021-10-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

American health & drug benefits

2012年5卷2期

94-101页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Impact of the removal of the monthly liver function test requirement for ambrisentan.

American health & drug benefits

相似文献

American health & drug benefits

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Impact of the removal of the monthly liver function test requirement for ambrisentan.

American health & drug benefits

相似文献

American health & drug benefits

相关期刊

检索历史清除